T-cell receptor recognizing H5N1 hemagglutinin-derived peptides (TCR-H5)

The T-cell receptor (TCR) recognizing H5-derived peptides presented by the Major Histocompatibility Complex (MHC) is a specialized protein complex on the surface of T lymphocytes that mediates the recognition of avian influenza A (H5N1) virus-infected cells. These TCRs specifically interact with viral epitopes, most notably peptides derived from the H5 hemagglutinin protein, such as the H5(58–66) or H5(259–267) sequences, presented by specific human leukocyte antigen (HLA) alleles like HLA-A*02:01 [1, 2]. This interaction is a cornerstone of the cellular immune response, where TCR binding to the peptide-MHC (pMHC) complex initiates intracellular signaling via the CD3 complex, leading to T-cell proliferation and the deployment of cytotoxic effector functions [3]. In therapeutic research, these TCR sequences are cloned and used to engineer TCR-T cells, providing a strategy for adoptive immunotherapy against highly pathogenic influenza strains that may evade antibody-mediated immunity [4]. However, the clinical application of such therapies faces hurdles, including the high diversity of MHC alleles in the human population and the risk of off-target recognition of similar self-peptides, which can cause severe adverse effects [5]. Citations: [1] PubMed: 20624918, [2] UniProt: P03467, [3] StatPearls: T-Cell Receptors, [4] PubMed: 28416510, [5] PubMed: 25646019.

Other names

H5-specific T-cell receptorHemagglutinin-specific TCRH5N1-specific TCRTCR recognizing H5/MHC

Engineered T cells expressing this TCR recognize and bind to H5-peptide/MHC complexes on the surface of infected cells, triggering T-cell activation, cytokine production, and direct lysis of the target cell.